A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
暂无分享,去创建一个
[1] H. Maeda,et al. Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.
[2] R. Begent,et al. Mathematical model of antibody targeting: important parameters defined using clinical data. , 2001, Physics in medicine and biology.
[3] J. Chatal,et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. B. Campbell,et al. Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Ferrari. Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.
[6] Andreas Plückthun,et al. PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5 , 2006, Journal of Biological Chemistry.
[7] Judit Erchegyi,et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.
[8] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[9] Robert Langer,et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.
[10] Christilyn P. Graff,et al. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. , 2003, Cancer research.
[11] W. Deen,et al. Structural determinants of glomerular permeability. , 2001, American journal of physiology. Renal physiology.
[12] P. L. Paine,et al. Drag coefficients for the movement of rigid spheres through liquid-filled cylindrical pores. , 1975, Biophysical journal.
[13] A. Karlström,et al. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. , 2007, Bioconjugate chemistry.
[14] S. Ross,et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. , 2007, Cancer research.
[15] S. Kanoh,et al. Polysaccharides as drug carriers: biodisposition of fluorescein-labeled dextrans in mice. , 1997, Biological & pharmaceutical bulletin.
[16] Michael M. Schmidt,et al. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability , 2008, Cancer Immunology, Immunotherapy.
[17] G. Griffiths,et al. Intracellular processing of 99Tcm-antibody conjugates. , 1998, Nuclear medicine communications.
[18] A. Wu,et al. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. , 2000, Bioconjugate chemistry.
[19] M. Dewhirst,et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.
[20] T. Jackson,et al. Mathematical and experimental analysis of localization of anti-tumour antibody–enzyme conjugates , 1999, British Journal of Cancer.
[21] L E Williams,et al. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. , 2001, Cancer biotherapy & radiopharmaceuticals.
[22] E. Yamada. THE FINE STRUCTURE OF THE RENAL GLOMERULUS OF THE MOUSE , 1955, The Journal of biophysical and biochemical cytology.
[23] J. Carlsson,et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. , 2006, Cancer research.
[24] D. Pressman,et al. Plasma and Blood Volumes of Mouse Organs, As Determined with Radioactive Iodoproteins.∗ , 1950, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[25] I. Bernstein,et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. , 1996, Cancer research.
[26] Y. Ikada,et al. Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification , 1997 .
[27] A. Karlström,et al. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[28] A. Plückthun,et al. Tumor Targeting of Mono-, Di-, and Tetravalent Anti-p185HER-2 Miniantibodies Multimerized by Self-associating Peptides* , 2001, The Journal of Biological Chemistry.
[29] P. Hudson,et al. Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.
[30] Michael M. Schmidt,et al. Factors determining antibody distribution in tumors. , 2008, Trends in pharmacological sciences.
[31] R. Jain,et al. Pore and fiber-matrix models for diffusive transport in normal and neoplastic tissues. , 1984, Microvascular research.
[32] M. Dewhirst,et al. Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. , 1999, Cancer research.
[33] Wolfgang A. Weber,et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.
[34] Andreas Plückthun,et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. , 2007, Journal of molecular biology.
[35] E. Ward,et al. Transcytosis and catabolism of antibody , 2002, Immunologic research.
[36] T. Allen. Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.
[37] K R Godfrey,et al. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. , 1989, Cancer research.
[38] G. Adams,et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.
[39] R K Jain,et al. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. , 1991 .
[40] P. Caliceti,et al. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.
[41] E. Gillette,et al. Morphometric analyses of the microvasculature of tumors during growth and after x‐irradiation , 1974, Cancer.
[42] R. Jain,et al. Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[43] W. Deen,et al. Effects of plasma proteins on sieving of tracer macromolecules in glomerular basement membrane. , 2001, American journal of physiology. Renal physiology.
[44] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.
[45] F. Curry,et al. Microvascular permeability. , 1999, Physiological reviews.
[46] S. Kneifel,et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor–Targeted Therapy for Insulinoma , 2007, Clinical Cancer Research.
[47] K. Dane Wittrup,et al. Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases , 2007, Journal of Nuclear Medicine.
[48] Min Zhao,et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. , 2004, American journal of physiology. Renal physiology.
[49] M. Sliwkowski,et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. , 2004, Molecular biology of the cell.
[50] Alastair H Kyle,et al. Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts , 2008, Clinical Cancer Research.
[51] R K Jain,et al. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. , 1989, Microvascular research.
[52] R. Jain. Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.